← Therapy pipeline
Investigational · Obesity development

ASC30

Ascletis

One small molecule explored as an oral tablet and long-acting depot.

GLP-1
Other study areas
Type 2 diabetes
Selected program areas, not approvals. See the full profile for individual trials.
Obesity stagePhase 3Updated as of November 2026
SponsorAscletis
TargetsGLP-1
RouteOral tablet + Injection
DevelopmentFormulations differ
01 / Evidence

Selected study results

U.S. oral dose-finding studyPlacebo-adjusted weight-loss differencePlacebo-adjusted weight-loss difference: −7.7 percentage points · 13 weeks · Phase 2
Phase 2 · Oral · Sponsor-reported numerical results

Placebo-adjusted weight-loss difference · 13 weeks

Study focus: Weight management

Placebo-adjusted difference, not the total change in the active arm.

Difference versus placebo
7.7 percentage points

Adults with obesity/overweight and a weight-related complication · 60 mg once daily after titration · Trial N=125 · Sponsor topline; placebo-adjusted estimate. Results & methods ↗

Short trial. This estimate does not describe the injectable depot formulation.

Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.

02 / How it works

Mechanism at a glance

GLP-1GLP-1Targeted
GIPGIP—
GCGglucagon—
AMYamylin—
OTHOther targets—
Explore the hormone anatomy ↗
03 / Development

Obesity stage by formulation

TabletOral tablet · Once daily
Phase 3Global Phase 3 AURORA-1 and AURORA-2 initiated; 72-week pivotal studies.
Depot injectionInjection · Monthly treatment; quarterly maintenance under study
Phase 2Phase 2 depot-efficacy results reported; next development stage not confirmed.
Milestone → next

Latest: Global Phase 3 oral chronic-weight-management program initiated in August 2026; two pivotal trials are registered. Phase 2 oral and depot studies have reported results.

Next: Ascletis expects topline results from the two oral AURORA studies in the third quarter of 2028. Injectable depot development is separate.

04 / Study records

Clinical study records

Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.

Obesity and weight-management studies

Phase 3 studies2 records

Phase 3

AURORA-1

Weight management
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Pivotal oral ASC30 study in adults with obesity or overweight and weight-related comorbidities; global chronic-weight-management program.

Phase 3

AURORA-2

Weight management with type 2 diabetes
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Pivotal oral ASC30 study in adults with obesity or overweight and type 2 diabetes; global chronic-weight-management program.

Phase 2 studies2 records

Phase 2

ASC30 depot-efficacy study

Weight management
Study: CompletedResults: No registry results posted yetStatus reviewed November 2026

Sponsor reported a 24-week U.S. Phase 2 depot-efficacy study; the linked registration began as a Phase I/IIa safety/PK study.

Phase 2a

ASC30 tablet dose-finding study

Weight management
Study: CompletedResults: No registry results posted yetStatus reviewed November 2026

13-week oral dose-finding study in adults with obesity or overweight and a weight-related comorbidity.